Zynerba: Repeated Trial Failures, Some Post Hoc Success (NASDAQ:ZYNE) | Seeking Alpha
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Form 8-K for Zynerba Pharmaceuticals INC filed 08/09/2022
Should You Buy Zynerba Pharmaceuticals Inc (ZYNE) Stock on Thursday?
Zynerba sinks after total failure in phase 2 cannabidiol trial | Fierce Biotech
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Zygel - Zynerba
FDA urged to approve Sarepta DMD drug by dozens of medical experts - STAT
Zygel's anticipated impact on underserved fragile X syndrome market
Zynerba Pharmaceuticals receives FDA approval for cannabinoid therapies
SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients (NASDAQ:ZYNE) | Seeking Alpha
Zynerba Pharmaceuticals Inc's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome, and other conditions
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Stan Banks - Director of CMC and Product Development - Zynerba Pharmaceuticals | LinkedIn
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th | ZYNE Stock News
Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products
